Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species

Iranian Journal of Microbiology

Volumn 8, Issue 6, 2016, Pages 410-417

  Rezaei Matehkolaei, Ali ^a   Shafiei, Shokoofe ^a   Zarei Mahmoudabadi, Ali ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Candida albicans; Candida vaginitis; Caspofungin; Clotrimazole; Fluconazole

Indexed keywords

CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; RESAZURIN;

ADULT; AGAR MEDIUM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; FEMALE; FUNGUS ISOLATION; HUMAN; KLUYVEROMYCES MARXIANUS; MAJOR CLINICAL STUDY; MIC50; MIC90; MIDDLE AGED; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VAGINA CANDIDIASIS; VAGINA FLORA; VAGINITIS;

EID: 85014661499     PISSN: 20083289     EISSN: 20084447     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Shokri H, Khosravi AR, Yalfani R. Antifungal efficacy of propolis against fluconazole-resistant Candida glabrata isolates obtained from women with recurrent vulvovaginal candidiasis. Int J Gynaecol Obstet 2011;114:158-159.
2. Zarei Mahmoudabadi A, Najafyan M, Alidadi M. Clinical study of Candida vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. Pak J Med Sci 2010;26:607-610.
3. Diba K, Namaki A, Ayatolahi H, Hanifian H. Rapid identification of drug resistant Candida species causing recurrent vulvovaginal candidiasis. Med Mycol J 2012;53:193-198.
4. Ray A, Ray S, George AT, Swaminathan N. Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection. Cochrane Database Syst Rev 2011(8):CD008739.
5. Mendling W, Brasch J, German Society for G, Obstetrics, Working Group for I, Infectimmunology in G, et al. Guideline vulvovaginal candidosis (2010) of the German society for gynecology and obstetrics, the working group for infections and infectimmunology in gynecology and obstetrics, the German society of dermatology, the board of German dermatologists and the German speaking mycological society. Mycoses 2012;55 Suppl 3:1-13.
6. Mohamadi J, Havasian MR, Panahi J, Pakzad I. Antifungal drug resistance pattern of Candida. spp isolated from vaginitis in Ilam-Iran during 2013-2014. Bioinformation 2015;11:203-206.
7. Hedayati MT, Taheri Z, Galinimoghadam T, Aghili SR, Yazdani Cherati J, Mosayebi E. Isolation of different species of Candida in patients with vulvovaginal candidiasis from Sari, Iran. Jundishapur J Microbiol 2015;8(4):e15992.
8. Shi XY, Yang YP, Zhang Y, Li W, Wang JD, Huang WM, et al. Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginal candidiasis in southern China. J Med Microbiol 2015;64(Pt 4):390-393.
9. Rasti S, Asadi MA, Taghriri A, Behrashi M, Mousavie G. Vaginal candidiasis complications on pregnant women. Jundishapur J Microbiol. 2014;7(2):e10078.
10. Mendling W, Brasch J, Cornely OA, Effendy I, Friese K, Ginter-Hanselmayer G, et al. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015;58 Suppl 1:1-15.
11. Gamarra S, Morano S, Dudiuk C, Mancilla E, Nardin ME, de Los Angeles Mendez E, et al. Epidemiology and antifungal susceptibilities of yeasts causing vulvovaginitis in a teaching hospital. Mycopathologia 2014;178(3-4):251-258.
12. Zarei Mahmoudabadi A, Najafyan M, Moghimipour E, Alwanian M, Seifi Z. Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis. Iran J Microbiol 2013;5:86-90.
13. Shan Y, Fan S, Liu X, Li J. Prevalence of Candida al bicans-closely related yeasts, Candida africana and Candida dubliniensis, in vulvovaginal candidiasis. Med Mycol 2014;52:636-640.
14. Seifi Z, Zarei Mahmoudabadi A, Zarrin M. Extracellular enzymes and susceptibility to fluconazole in Candida strains isolated from patients with vaginitis and healthy individuals. Jundishapur J Microbiol 2015;8(3):e20162.
15. Li J, Shan Y, Fan S, Liu X. Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal Candidiasis. Mycopathologia 2014;178(3-4):279-283.
16. Alfouzan W, Dhar R, Ashkanani H, Gupta M, Rachel C, Khan ZU. Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait. J Mycol Med 2015;25:23-28.
17. Wang FJ, Zhang D, Liu ZH, Wu WX, Bai HH, Dong HY. Species distribution and In vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin Med J 2016;129:1161-1165.
18. Liu XP, Fan SR, Peng YT, Zhang HP. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. J Mycol Med 2014;24:106-111.
19. Nasrollahi Z, Yadegari MH, Roudbar Mohammadi S, Roudbary M, Hosseini Poor M, Nikoomanesh F, et al. Fluconazole resistance Candida albicans in females with recurrent vaginitis and Pir1 overexpression. Jundishapur J Microbiol 2015;8(9):e21468.
20. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-299.
21. Veroux M, Macarone M, Fiamingo P, Cappello D, Gagliano M, Di Mare M, et al. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. Transplant Proc 2006;38:1037-1039.
22. Mihu MR, Pattabhi R, Nosanchuk JD. The impact of antifungals on toll-like receptors. Front Microbiol 2014;5:99.
23. Leon-Gil C, Ubeda-Iglesias A, Loza-Vazquez A, de la Torre MV, Raurich-Puigdevall JM, Alvarez-Sanchez B, et al. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study. Revista Espanola de Quimioterapia 2012;25:274-282.
24. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-1571.
25. Zarei Mahmoudabadi A, Rezaei-Matehkolaei A, Ghanavati F. The susceptibility patterns of Candida species isolated from urine samples to posaconazole and caspo fungin. Jundishapur J Mmicrobiol 2015;8(3):e24298.
26. White TJ, Bruns T, Lee S, Taylor J (1990). Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: nPCR - Protocols and Applications - A Laboratory Manual. Academic Press, Cambridge, Massachusetts, USA pp.315-3322.
27. Mohammadi R, Mirhendi H, Rezaei-Matehkolaei A, Ghahri M, Shidfar MR, Jalalizand N, et al. Molecular identification and distribution profile of Candida species isolated from Iranian patients. Med Mycol 2013;51:657-663.
28. Elshikh M, Ahmed S, Funston S, Dunlop P, McGaw M, Marchant R, et al. Resazurin-based 96-well plate microdilution method for the determination of minimum inhibitory concentration of biosurfactants. Biotechnol Lett 2016;38:1015-1019.
29. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturvedi V, et al. Refrence method for broth dilution abtifungal suceptibility testing of yeasts; approved standard-third edition. M27-A3 2008;28(14).
30. Guzel AB, Aydin M, Meral M, Kalkanci A, Ilkit M. Clinical characteristics of Turkish women with Candida krusei vaginitis and antifungal susceptibility of the C. krusei isolates. Infect Dis Obstet Gynecol 2013;2013:698736.
31. Donders GG, Bellen G, Mendling W. Management of recurrent vulvo-vaginal candidosis as a chronic illness. Gynecol Obstet Invest 2010;70:306-321.
32. Zhu YX, Li T, Fan SR, Liu XP, Liang YH, Liu P. Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. Health Qual Life Outcomes 2016;14:65.
33. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016;214: 15-21.
34. Akimoto-Gunther L, Bonfim-Mendonca Pde S, Takahachi G, Irie MM, Miyamoto S, Consolaro ME, et al. Highlights regarding host predisposing factors to recurrent vulvovaginal candidiasis: chronic stress and reduced antioxidant capacity. PloS One 2016;11(7):e0158870.
35. Fornari G, Vicente VA, Gomes RR, Muro MD, Pinheiro RL, Ferrari C, et al. Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. Brazil J Microbiol 2016;47(2):373-380.
36. Malazy OT, Shariat M, Heshmat R, Majlesi F, Alimohammadian M, Tabari NK, et al. Vulvovaginal candidiasis and its related factors in diabetic women. Taiwan J Obstet Gynecol 2007;46(4):399-404.
37. Mahmoudi Rad M, Zafarghandi S, Abbasabadi B, Tavallaee M. The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population. Eur J Obstet Gynecol Reprod Biol 2011;155(2):199-203.
38. Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002;35:1066-1070.
39. Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res 2007;126:216-219.
40. Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004;48:1773-1777.
41. Khoursandi M, Modares Gilani M, Khosravi A. Recovery and recurrence of vaginal candidiasis after oral and intravaginal treatment. J Qazvin Univ Med Sci 2000(14):25-29.
42. Diaz MC, Camponovo R, Araya I, Cerda A, Santander MP, Carrillo-Munoz AJ. [Identification and in vitro antifungal susceptibility of vaginal Candida spp. isolates to fluconazole, clotrimazole and nystatin]. Revista Espanola de Quimioterapia 2016;29:151-154.
43. Moges B, Bitew A, Shewaamare A. Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis. Int J Microbiol 2016;2016:3037817.
44. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006;50:2058-2063.